Novartis chief to employees: We need a quality reboot

It has been a tough year for Novartis CEO Joseph Jimenez. In the course of 9 months, the company ($NVS) received a three-plant FDA warning letter, closed its key OTC plant and had to tell shareholders that revenues slid 4% because the manufacturing mess kept it from having its most popular consumer products. So, Jimenez says maybe it is time the company thinks differently about quality. Report